Recovery, safety, and tolerability of a solvent/detergent-treated and prion-safeguarded transfusion plasma in a randomized, crossover, clinical trial in healthy volunteers

Transfusion

Volumn 53, Issue 9, 2013, Pages 1906-1917

  Jilma Stohlawetz, Petra ^a   Kursten, Friedrich W ^a   Horvath, Michaela ^a   Leitner, Gerda ^a   List, Jana ^a   Marcek, Jana ^a   Quehenberger, Peter ^a   Schwameis, Michael ^a   Bartko, Johann ^a   Derhaschnig, Ulla ^a   Jilma, Bernd ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; OCTAPLAS; PLASMIN INHIBITOR;

ABDOMINAL PAIN; ALLERGIC RHINITIS; ANAPHYLACTIC SHOCK; ARTICLE; BLOOD SAMPLING; COLLAPSE; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; CYSTITIS; DIZZINESS; DRUG SAFETY; DYSGEUSIA; DYSPHONIA; EAR DISEASE; EDEMA; EPISTASIS; ERYTHEMA; FEMALE; HEADACHE; HERPES SIMPLEX; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; MALE; NORMAL HUMAN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PLASMA TRANSFUSION; PLASMAPHERESIS; POLYURIA; PRION; RANDOMIZED CONTROLLED TRIAL; RASH; RHINITIS; SIDE EFFECT; SKIN ATROPHY; STRESS FRACTURE; TACHYCARDIA; TENDINITIS; THORAX PAIN; THROMBOPHLEBITIS; URTICARIA; VERTIGO;

ADULT; BLOOD COMPONENT TRANSFUSION; CROSS-OVER STUDIES; DETERGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLASMA; SOLVENTS;

EID: 84883896424     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12075     Document Type: Article

References (23)

1. Octapharma. Summary of product characteristics, Octaplas. 2009. [cited 2011 Aug 31]. Available from: URL: http://emc.medicines.org.uk/medicine/21929/ SPC/Octaplas+SPC/.
2. Solheim BG,. Pathogen reduction of blood components. Transfus Apher Sci 2008; 39: 75-82.
3. Heger A, Svae TE, Neisser-Svae A, Jordan S, Behizad M, Römisch J,. Biochemical quality of the pharmaceutically licensed plasma OctaplasLG® after implementation of a novel prion protein (PrPSc) removal technology and reduction of the solvent/detergent (S/D) process time. Vox Sang 2009; 97: 219-225.
4. Neisser-Svae A, Bailey A, Gregori L, Heger A, Jordan S, Behizad M, Reichl H, Römisch J, Svae TE,. Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)-treated plasma OctaplasLG®. Vox Sang 2009; 97: 226-233.
5. Jilma-Stohlawetz P, Kursten FW, Walasek C, Horvath M, Leitner G, List J, Quehenberger P, Schwameis M, Bartko J, Jilma B,. Safety of a universal, virus-inactivated and prion-depleted, pharmaceutical-quality plasma: a randomized, double-blind, clinical trial in healthy volunteers. Transfusion 2011; 51: 1228-1240.
6. Jilma-Stohlawetz P, Knöbl P, Gilbert JC, Jilma B,. The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease. Thromb Haemost 2012; 108: 284-290.
7. Siller-Matula JM, Miller I, Gemeiner M, Plasenzotti R, Bayer G, Mesteri I, Fabry A, Petroczi K, Nöbauer K, Razzazi-Fazeli E, Planchon S, Renaut J, Quehenberger P, Selzer E, Jilma B,. Continuous thrombin infusion leads to a bleeding phenotype in sheep. Thromb Res 2012; 130: 226-236.
8. ICH Topic E 9. Statistical Principles for Clinical Trials. Note for guidance on statistical principles for clinical trials. (CPMP/ICH/363/96) 2009. [cited 2012 Aug 31]. Available from: URL: http://www.emea.europa.eu/docs/en-GB/ document-library/Scientific-guideline/2009/09/WC500002928.pdfTRANSMISSION
9. CHMP. Guideline on the Investigation of Bioequivalence CPMP/EWP/QWP/1401/98 Rev. 1/ Corr. 2010. [cited 2012 Aug 31]. Available from: URL: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/ 2010/01/WC500070039.pdf
10. FDA. Guidance for industry. Statistical approaches to establishing bioequivalence. 2001. [cited 2011 Aug 31]. Available from: URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm070244.pdf
11. Lawrie AS, Green L, Canciani MT, Mackie IJ, Peyvandi F, Scully MA, Machin SJ,. The effect of prion reduction in solvent/detergent-treated plasma on haemostatic variables. Vox Sang 2010; 99: 232-238.
12. Osselaer JC, Debry C, Goffaux M, Pineau J, Calomme G, Dubuc E, Chatelain B, Vandendaele MC, Hsu J, Rheinschmidt M, Lin L,. Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen. Transfusion 2008; 48: 108-117.
13. Haubelt H, Blome M, Kiessling AH, Isgro F, Bach J, Saggau W, Hellstern P,. Effects of solvent/detergent-treated plasma and fresh-frozen plasma on haemostasis and fibrinolysis in complex coagulopathy following open-heart surgery. Vox Sang 2002; 82: 9-14.
14. Hambleton J, Wages D, Radu-Radulescu L, Adams M, MacKenzie M, Shafer S, Lee M, Smyers J, Wiesehahn G, Corash L,. Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion 2002; 42: 1302-1307.
15. Frietsch T, Fessler H, Kirschfink M, Nebe T, Waschke KF, Lorentz A,. Immune response to autologous transfusion in healthy volunteers: WB versus packed RBCs and FFP. Transfusion 2001; 41: 470-476.
16. Simonsen AC, Sørensen H,. Clinical tolerance of methylene blue virus-inactivated plasma. A randomized crossover trial in 12 healthy human volunteers. Vox Sang 1999; 77: 210-217.
17. Martí-Carvajal AJ, Solà I, González LE, Leon de Gonzalez G, Rodriguez-Malagon N,. Pharmacological interventions for the prevention of allergic and febrile non-haemolytic transfusion reactions. Cochrane Database Syst Rev 2010;(6): CD007539.
18. Geiger TL, Howard SC,. Acetaminophen and diphenhydramine premedication for allergic and febrile nonhemolytic transfusion reactions: good prophylaxis or bad practice? Transfus Med Rev 2007; 21: 1-12.
19. Scully M, Longair I, Flynn M, Berryman J, Machin SJ,. Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura. Vox Sang 2007; 93: 154-158.
20. Stohlawetz P, Kapiotis S, Seidl D, Hergovich N, Zellner M, Eichler HG, Stiegler G, Leitner G, Höcker P, Jilma B,. Safety issues of plateletpheresis: comparison of the effects of two cell separators on the activation of coagulation, fibrinolysis, and neutrophils and on the formation of neutrophil-platelet aggregates. Transfusion 1999; 39: 420-427.
21. Mayr WR,. Haemovigilance: are there significant differences among plasma products? Transfus Apher Sci 2010; 43: 407-409.
22. Flesland O,. A comparison of complication rates based on published haemovigilance data. Intensive Care Med 2007; 33 (Suppl. 1): S17-21.
23. Krusius T, Auvinen MK, Nikkinen L,. Introduction of Octaplas in clinical use decreased the rate of severe adverse reactions. Vox Sang 2009; 96 (Suppl. 1): 3A-S13-03.